FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/14/2026

1. ORCL
2. NVDA
3. SPY
4. USO
5. SRRK
6. DFTX
7. AZN
8. CGEM
9. SATL
10. LYNX

Go back to FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
Lilly (Eli) & Co. (NYSE: LLY) Delayed: 1147.30 +31.60 (2.83%)
Previous Close $1115.70    52 Week High $88.16 
Open $1142.20    52 Week Low $67.88 
Day High $1153.95    P/E 265.58 
Day Low $1130.50    EPS $4.32 
Volume 812,631